KushCo Holdings Inc News
Greenlane and KushCo Combine in All-Stock Pot-Packaging Merger
Cannabis packaging and accessories makers Greenlane and KushCo agree to merge in an all-stock deal that will value the combined company at more than $400 million.
Chevron, Anadarko, JPMorgan, Wells Fargo and Uber - 5 Things You Must Know
U.S. stock futures are rising as Wall Street looks to earnings from several big U.S. banks including JPMorgan Chase and Wells Fargo; Uber discloses in a filing for its initial public offering it may never be profitable; Disney unveils its streaming service.
Disney, Amazon, Bed Bath & Beyond, National Enquirer - 5 Things You Must Know
U.S. stock futures turn higher as minutes from the Federal Reserve's meeting in March showed that most central bank officials believe the current pace of U.S. economic expansion warrants leaving interest rates at their current levels for the rest of 2019; Walt Disney will unveil its streaming service; Amazon buys Canvas, a warehouse robotics maker.
Canopy Growth Soars as Piper Jaffray Recommends the Cannabis Stock
Canopy Growth climbs after Piper Jaffray analyst Michael Lavery initiate coverage on the Canadian cannabis company.
Cowen's Cannabis Analyst Raises 2030 U.S. Market Forecast to $80 Billion
That forecast is based on the hypothesis that cannabis receives full federal legalization by 2030.
These 3 Marijuana-Related Stocks are Ripe for Takeover
In search of additional Canadian producers.
Private Equity Has Become the Lifeblood of the Legal Weed Industry
'This is a capital starved industry,' says one CEO. Here's how private equity is answering the call.
Here's How Some Major Players in Legal Weed Use Regulation to Their Advantage
No federal legality, no problem. These cannabis firms are using the complicated regulatory landscape to win business and churn profits.
Trump's Potential Return to Twitter Under Musk Hits Digital World
Digital World Acquisition, a company attempting to merge with former President Donald Trump's media group Truth Social, faces a new challenge.
Bluebird Bio's 2nd Approval Doesn't Guarantee Survival
Investors hoping for a revival at the struggling biotech might want to temper their expectations.